Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLT PET imaging in EGFR-mutant non-small cell lung cancer treated with gefitinib
NL-OMON24060Active, not recruiting
- Sponsor
- Amsterdam UMC
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Amsterdam UMC. Primary endpoint: Simplified FLT PET measures and pharmacokinetic modeling results. Started Sep 2012; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON24060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24060.